First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Overview of attention for article published in Clinical Cancer Research, March 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

news: 1 news outlet
policy: 1 policy source
twitter: 11 X users

patent: 4 patents
wikipedia: 1 Wikipedia page

Readers on

mendeley: 64 Mendeley

So far, Altmetric has seen 14 X posts from 11 X users, with an upper bound of 112,315 followers.

RT @CCR_AACR: First in Human study: Dose escalation of cemiplimab in advanced tumors. https://t.co/iEzObqP9dp https://t.co/2QuIadrVb6

First in Human study: Dose escalation of cemiplimab in advanced tumors. https://t.co/iEzObqP9dp https://t.co/2QuIadrVb6

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies https://t.co/xpuxEMJbsi

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 10 additional X posts.